| Alpha -1- Microglobulin (α1M) as an Early Biomarker in Renal Extrahepatic Manifestations of HCV-infection (NCT05276700) | Assiut University | 2022-07-15 |
| Pharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in HCV-infected Children (NCT05854511) | Ain Shams University | 2022-06-05 |
| A Setting Focus Overdose Prevention Intervention (NCT05320835) | Johns Hopkins Bloomberg School of Public Health | 2022-04-30 |
| Appalachian Partnership to Reduce Disparities (Aim 2) (NCT04378439) | Wake Forest University Health Sciences | 2022-04-01 |
| Effect of New Oral Treatment for Hepatitis C Virus on Seminal Parameters (NCT05616598) | Benha University | 2022-03-01 |
| HCV, HBV, HIV Testing During Consultation With Anesthesiologist (NCT04286347) | Assistance Publique - Hôpitaux de Paris | 2021-08-05 |
| Predictive Models of Hepatic Decompensation and Survival Outcomes in Pediatric Patients With Cirrhosis (NCT05181332) | West China Hospital | 2021-01-01 |
| Prognostic Model of HCV-related Disease Progression After DAAs (NCT04631640) | Peking University People's Hospital | 2020-12-01 |
| Integrated HIV Prevention and HCV Care for PWID (NCT03981445) | Columbia University | 2019-11-14 |
| Access Anti-HCV Assay European Union (EU) Clinical Trial Protocol (NCT04971330) | Beckman Coulter, Inc. | 2019-11-04 |
| Utilization of Hepatitis C Positive Kidneys in Negative Recipients (NCT03801707) | Ohio State University | 2019-03-22 |
| Impact of Metabolic Changes and Vitamin D Status on Virological Response in Patients With HCV Infection Treated by DAAs (NCT03820102) | Assiut University | 2019-03-01 |
| Safety of Sofosbuvir ,Daclatasvir in HCV Patients and RAVS in Resistent and Relapsed Cases (NCT03572140) | Assiut University | 2018-07-01 |
| Chronic Hepatitis C Treatment in Egyptian Children With Gaucher Disease. (NCT03721627) | Mansoura University Children Hospital | 2018-04-03 |
| Bioequivalence Study of Crushed Sofosbuvir/Velpatasvir Compared to the Whole Tablet (NCT03389061) | Radboud University Medical Center | 2018-04-01 |
| Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China (NCT03288636) | Ascletis Pharmaceuticals Co., Ltd. | 2017-08-08 |
| A Clinical Trial of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotypes 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A (NCT03105349) | Fundacion SEIMC-GESIDA | 2017-07-01 |
| Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects. (NCT03362814) | Ascletis Pharmaceuticals Co., Ltd. | 2017-07-01 |
| Hepatitis C Treatment to Prevent HIV, Initiate Opioid Substitution Therapy, and Reduce Risky Behavior (NCT03221309) | University of Maryland, Baltimore | 2017-05-01 |
| Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects (NCT03092375) | University of Florida | 2017-04-20 |
| Post Sustained Virological Response (SVR) Hepatocellular Carcinoma (HCC) Screening (NCT02833298) | Icahn School of Medicine at Mount Sinai | 2016-11-01 |
| A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2) (NCT02692703) | AbbVie | 2016-04-22 |
| Cost Effective Non Invasive Diagnostic Modalities and Predictive Model for Development and Progression of Fibrosis Among Patients With Hepatitis B, Hepatitis C Infection or Non Alcoholic Fatty Liver Disease (NCT02658786) | Institute of Liver and Biliary Sciences, India | 2016-01-01 |
| A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection (NCT02604017) | AbbVie | 2015-10-01 |
| Sofosbuvir and Simeprevir Versus Sofosbuvir and Ribavirin in Treatment of HCV (NCT03069001) | Ain Shams University | 2015-06-01 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy (NCT02446717) | AbbVie | 2015-04-01 |
| Impact of Interferon-free Treatment for Hepatitis C Virus (HCV) on Blood Cells and Factors in Blood (NCT02718573) | Icahn School of Medicine at Mount Sinai | 2015-01-01 |
| Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt (NCT02247401) | AbbVie | 2014-11-04 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 Infection (NCT02243280) | AbbVie | 2014-08-01 |
| Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection (NCT02452814) | Hoffmann-La Roche | 2014-05-07 |
| TD-6450 MAD Study in HCV Infected Subjects (NCT02116543) | Theravance Biopharma | 2014-05-01 |
| A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C (NCT01842451) | Vertex Pharmaceuticals Incorporated | 2013-06-01 |
| A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV) (NCT01221298) | AbbVie (prior sponsor, Abbott) | 2010-10-01 |
| A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 (NCT01074008) | AbbVie (prior sponsor, Abbott) | 2010-03-01 |
| VX-950-TiDP24-C134: Drug-drug Interaction Trial Between Combination of Efavirenz and Tenofovir Disoproxil Fumarate and Different Dosages of Telaprevir on Healthy Volunteer (NCT00828789) | Tibotec BVBA | 2009-02-01 |
| Radiolabel ADME (Absorption, Distribution, Metabolism, and Excretion) Study Of [14C] PF-00868554 In Healthy Adult Male Subjects (NCT00823745) | Pfizer | 2009-01-01 |
| TMC435350-TiDP16-C109: A Safety Study for TMC435350 in an Oral Solution Containing Either 100, 200 or 400 mg Equivalent of TMC435350 or Placebo in Healthy Japanese Male Volunteers (NCT00752544) | Tibotec Pharmaceuticals, Ireland | 2008-08-01 |
| TMC435350-TiDP16-C106: A Phase I Trial to Compare the Bioavailability and Plasma Pharmacokinetics After a Single Oral Dose of TMC435350 of 2 Different Solid Formulations Relative to a Powder Blend Capsule (NCT00752648) | Tibotec Pharmaceuticals, Ireland | 2008-07-01 |
| Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures (NCT00678587) | GlaxoSmithKline | 2008-06-01 |
| TMC435350-TiDP16-C105: Phase I, 3-way Crossover, Drug-drug Interaction Between TMC435350 and Rifampin After Multiple Dosing. (NCT00741169) | Tibotec Pharmaceuticals, Ireland | 2008-06-01 |
| An Open Label Non-Randomized Dose Escalating Trial to Assess Safety and Tolerability of Alb-Interferon Alfa 2b Every Two Weeks With Ribavirin Among HIV/HCV Coinfected Individuals (NCT00489385) | National Institute of Allergy and Infectious Diseases (NIAID) | 2007-06-18 |